The Effect of Trimetazidine On Cardiac Haemodynamics and Mitochondrial Function in Wild-Type Transthyretin Amyloidosis
In ATTRwt, treatment with trimetazidine did not improve mPAWP or cardiac mitochondrial oxidative phosphorylation capacity compared with placebo.
Authors
- Tor Skibsted Clemmensen (ORCID: https://orcid.org/0000-0002-6042-6404)
- Steen Hvitfeldt Poulsen (ORCID: https://orcid.org/0000-0002-9586-835X)
- Anne M. Dybro (ORCID: https://orcid.org/0000-0003-3175-9725)
- Bertil Ladefoged (ORCID: https://orcid.org/0000-0002-3749-6789)
- Julian D. Gillmore (ORCID: https://orcid.org/0000-0001-6174-9232)
- Anders Lehmann Dahl Pedersen (ORCID: https://orcid.org/0000-0002-3258-5192)
Institutions
- The Royal Free Hospital (GB)
- Aarhus University Hospital (DK)
- Amyloidosis Foundation (US)
- University College London (GB)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1002/ehf2.15181
- Citations
- 2
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Karen Elise Jensens Fond